We’re in the year of the biotech buyout, and here are five prime targets
January 23, 2017 at 05:17 AM EST
One catalyst: Big drug companies are running out of ideas, writes Michael Brush.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|